For Health Care Providers:

As a health care provider, we are happy to help. Please call us at (877) 886-6739. For more specific information regarding Breast Cancer Index, please fill out the short form below.

For Patients/Caregivers:

Your journey is important to us and our Patient Services Team is here to listen to your concerns and address your questions. Feel free to give us a call or send us an email. We are more than happy to assist you.

Here's how to contact our Patient Services Team:

7AM - 3:30PM (Pacific)

Make a Payment

Biotheranostics, Inc.
9640 Towne Centre Drive
San Diego CA, 92121

Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.